New York, NY – February 11, 2015 – (Global Newswire) – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, in an underwritten public offering of 5,111,110 shares of the company’s common stock. The gross proceeds from this offering are approximately $23 million. Trovagene intends to use the net proceeds from this offering to fund its research and development activities and for working capital and other general corporate purposes.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Tara Guarneri-Ferrara.
[starbox id=1]
